DS
Therapeutic Areas
Humacyte Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Symvess™ (ATEV) | Vascular Trauma Repair | Approved |
| ATEV (HUM-001) | Arteriovenous (AV) Access for Hemodialysis | Phase 3 |
| ATEV | Peripheral Arterial Disease (PAD) | Phase 2/3 |
| BioVascular Pancreas™ | Type 1 Diabetes | Preclinical |
| Lung | Respiratory Disease | Preclinical |
| Urinary Conduit | Bladder Cancer/Cystectomy | Preclinical |
| Tracheal Replacement | Tracheal Damage/Disease | Preclinical |
| Esophageal Replacement | Esophageal Disease | Preclinical |
Leadership Team at Humacyte
LE
Laura E. Niklason, M.D., Ph.D.
Founder, President, Chief Executive Officer
SP
Shamik Parikh, M.D.
Chief Medical Officer
SO
Sabrina Osborne, GPHR, SPHR, CPC
Chief People Officer
LM
Lisa Molyneux
Executive Vice President, Enterprise Planning & Analysis
HC
Heather Connelly, Ph.D.
Executive Vice President, Regulatory Affairs & Quality